Printer Friendly
The Free Library
19,604,538 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Applied Spine Adds Investigational Site for IDE Trial.


Allegheny General Hospital newest site for Stabilimax([R]) IDE enrollment

ROCKY HILL, Conn. -- Applied Spine Technologies (www.appliedspine.com) announces the first patient surgery at Allegheny General Hospital in Pittsburgh, Pennsylvania, as part of their FDA approved Investigational Device Exemption (IDE) clinical trial designed to evaluate the safety and effectiveness of the Stabilimax[R] Dynamic Spine Stabilization System. The surgery was performed by Donald M. Whiting, M.D. on October 26th. Allegheny General Hospital is the latest clinical site to participate in the Stabilimax trial.

"We are very pleased to welcome Dr. Whiting and the entire spine team at Allegheny General as our newest investigational site," said Craig Corrance, Chief Executive Officer of Applied Spine. "Allegheny General Hospital's status as a nationally recognized comprehensive spine Center of Excellence reflects our strategy of partnering with leading U.S. spine facilities for the duration of our IDE clinical trial."

About Applied Spine Technologies Inc., and Stabilimax[R]

Applied Spine Technologies Inc., headquartered in Rocky Hill, Connecticut, is developing the Stabilimax Dynamic Spine Stabilization System, a posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion. Stabilimax is expected to offer numerous advantages over current spinal fixation products and even new artificial disc products--including a much less invasive and less traumatic implant procedure, maintenance of spine motion and disc function, and the potential to prevent or slow adjacent-segment disc disease.

About the IDE Clinical Trial

Applied Spine Technologies, Inc. recently received permission from the FDA to resume a multi-center, randomized, controlled clinical trial to compare posterior dynamic stabilization using the Stabilimax[R] Dynamic Spine Stabilization System to traditional spinal fusion stabilization to treat degenerative lumbar spinal stenosis. AST has enrolled more than 100 patients to date.

Stabilimax is an investigational device in the United States. It is limited by United States (U.S.) Federal Law for investigational use only.

COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U1CT
Date:Oct 28, 2009
Words:311
Previous Article:Research and Markets: Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy.
Next Article:IBBS Debuts New Bandwidth Management and Birth Certificate Tools at SCTE Cable-Tec Expo in Denver.
Topics:



Related Articles
ORTHOFIX GETS FDA APPROVAL FOR INVESTIGATION OF CERVICAL-STIM.
FDA GRANTS INVESTIGATIONAL DEVICE EXEMPTION FOR VIROSEQ.
Thoratec submits IDE to FDA to expand number of patients in trial of its LVAS system.
FDA approves MicroMed request to supplement its IDE-approved destination therapy trial.
MED ENCLOSURE SUBMITS IDE FOR MEDCLOSE VCS F-A-S-T TRIAL.
Thoratec receives FDA approval of continued access protocol for bridge arm of its LVAD phase II trial.
ViaCell announces FDA has conditionally approved IDE to begin clinical trial of ViaCyte in oocyte cryopreservation.
FDA APPROVES PLC SYSTEMS PIVOTAL TRIAL OF RENALGUARD IN U.S.
FDA publishes new guidance for Phase I clinical trials.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles